How to Qualify a Hormone API Supplier for US Manufacturing

To qualify hormone api supplier us manufacturers can approve, score the exact API and manufacturing site across six evidence areas. Approve only after the supplier clears five hard stops on source traceability, batch evidence, US program fit, quality controls, and change management.

A GMP certificate starts the review. It does not identify the API form, prove a batch meets your specification, or show that a DMF supports your submission.

How to Qualify Hormone API Supplier US Programs Can Approve

Start with the hard stops. Do not request a commercial quotation until the supplier can answer them.

Hard stops

1. Name the exact API, including salt, ester, polymorph, particle-size requirement, and intended dosage route.
2. Identify the original manufacturer, full manufacturing-site address, legal seller, and supplied batch.
3. Provide an authentic, batch-specific certificate of analysis with limits and numerical results.
4. State the US use: compounding, IND, NDA, ANDA, or another defined program.
5. Map any distributor, broker, repacker, relabeller, storage site, and transport handoff.

FDA Q7 requires distributors and repackers to retain traceability records, including the original manufacturer, batch number, transport records, and authentic COAs. FDA Q7

Our rule of thumb: approve at 85 points or more with no hard stops. Use 70 to 84 points only for limited development work with named owners and deadlines for missing evidence. Reject the source below 70 points, or whenever a hard stop remains unresolved.

The score is a buyer tool, not an FDA threshold. ICH Q9 says the effort and documentation used for quality-risk management should match the level of risk. ICH Q9

Write the Requirement Before You Request Documents

Write a one-page material brief before contacting suppliers. The brief prevents the common error of qualifying a company’s hormone catalogue instead of the material your formulation needs.

Include these fields:

• Exact chemical name and CAS number
• Salt, ester, hydrate, polymorph, or particle-size requirement
• Dosage form and route, such as oral solid, transdermal, injectable, or implant
• Target specification and applicable pharmacopoeial standard
• Development, validation, or commercial stage
• Annual volume, target batch size, and launch timing
• US regulatory pathway and importer responsibility

“Testosterone” is not a complete requirement if the formulation needs testosterone enanthate. “Progesterone” is not complete if the dosage route, particle-size range, or monograph basis changes the material specification.

For compounding programs, identify whether the facility operates under section 503A or 503B before selecting the API. FDA tells compounders to know their API supplier, assess the testing performed, use valid COAs, and meet the applicable bulk-drug-substance conditions. FDA compounding guidance

Review GMP, Containment, and Supply-Chain Control

Ask for GMP evidence that applies to the proposed manufacturing site and the activities performed there. Review the certificate issuer, site address, scope, date, and the product or activity covered.

Then request a short quality package covering:

• Quality-unit responsibilities
• Recent inspection or audit information
• Deviations, out-of-specification investigations, and CAPA summary
• Contamination-control approach
• Repackaging, relabelling, and storage controls
• Complaint and recall contacts

Steroid APIs can require more than general GMP evidence. FDA Q7 says dedicated production areas should be considered for certain steroids with high pharmacological activity or toxicity, unless validated inactivation or cleaning procedures are established and maintained. FDA containment guidance

Ask the supplier to show the containment rationale, equipment segregation, HVAC controls where relevant, and cleaning-validation approach. A generic statement that the facility handles steroids does not answer those questions.

For a deeper capability review, use our API manufacturing capabilities checklist.

Test the Route, Impurities, and Residual Solvents

Ask for a process summary at the level the supplier can disclose. The goal is to connect the manufacturing route to the controls that protect your finished product.

Request these records:

• Current API specification
• Typical-batch impurity profile
• Related-substances method and acceptance criteria
• Residual-solvent assessment
• Impurity trend data or change history
• Elemental impurities, microbiological limits, or endotoxin controls where the API and route require them

FDA Q7 says manufacturers should establish an impurity profile for each API made by a controlled process. The profile should identify or characterize observed impurities and show their ranges. FDA impurity guidance

Residual-solvent testing should focus on solvents used or produced during manufacturing or purification. ICH Q3C classifies solvent risks and sets the framework for acceptable patient exposure. ICH Q3C

Do not use a single HPLC purity percentage as the approval decision. A high assay result can sit beside an unacceptable related substance, residual solvent, wrong polymorph, or unsuitable particle-size profile.

Check the COA, Methods, and Reference Standards

Request a current COA for a representative batch, not a generic certificate. FDA Q7 says the COA should include the API name, grade where relevant, batch number, release date, every test performed, acceptance limits, and numerical results. COA requirements

Review the COA against your purchase specification. Check:

• Identity, assay, and related substances
• Residual solvents and water content
• Physical attributes that affect your dosage form
• Retest or expiry date
• Storage condition and package configuration
• Original manufacturer and testing laboratory identity

Ask which methods release the batch and whether the methods are validated or verified for the intended use. FDA Q7 also requires documented sourcing, storage, and use of primary reference standards. Reference-standard controls

A finished-drug manufacturer that accepts supplier test results still needs to establish the supplier’s analytical reliability and perform at least one specific identity test on the incoming component. FDA testing Q&A

Use our steroid API COA checklist when comparing a supplier COA against a purchase specification.

Match US Filing Support to the Actual API

A Type II Drug Master File, or DMF, can hold confidential information about a drug substance, manufacturing process, or site. It does not approve the API, supplier, or finished drug product.

FDA reviews DMF information only when an IND sponsor or application holder references it with a Letter of Authorization, or LOA. FDA states plainly that a DMF is never approved or disapproved on its own. FDA DMF guidance

For an IND, NDA, or ANDA program, ask these six questions:

1. Who holds the Type II DMF?
2. What exact API form does it cover?
3. Which manufacturing site does it cover?
4. Is the file current for the planned program?
5. Can the holder issue an applicant-specific LOA?
6. Who responds if FDA raises a deficiency?

Also request the change-notification process. FDA says DMF holders must notify each affected applicant or sponsor of pertinent changes well before making them. DMF change notices

For the first supplier inquiry, send a structured steroid API RFQ that asks for the API form, site, batch documentation, and filing support together.

Put Supply Continuity in the Quality Agreement

A supplier can make a successful development batch and still fail a commercial program. Test continuity before commercial approval.

Ask for the commercial batch range, lead-time assumptions, forecast process, critical starting-material dependencies, storage requirements, shipping lane, and contingency plan. Tie those answers to the named manufacturing site.

The quality agreement should require advance notification of changes to the process, site, starting materials, specification, method, packaging, and outsourced activity. FDA Q7 calls for a formal change-control system for changes that could affect API production or control. FDA change control

ICH Q10 adds that change management should use risk management, assess potential effects on regulatory filings, involve appropriate experts, and confirm that the change did not harm product quality. ICH Q10

FAQs

Does a Type II DMF Mean FDA Approved the Hormone API Supplier?

No. FDA does not approve or disapprove a DMF by itself. A DMF can support an IND, NDA, ANDA, or another referenced submission when the holder provides the required LOA. FDA DMF guidance

How Often Should a Hormone API Supplier Be Requalified?

Requalify on a risk-based schedule and whenever a material change occurs. Give higher-risk APIs, new sites, potent steroid processes, recurring deviations, and filing-dependent programs more frequent review than established low-risk sources. ICH Q9

Can a Distributor Be Qualified for Hormone API Supply?

Yes, when the distributor identifies the original manufacturer, preserves batch traceability, and transfers quality and regulatory information. FDA Q7 expects distributors and repackers to maintain those records and provide the original manufacturer and batch number to customers. Supply-chain traceability

At Aarise Pharma, we help formulation teams align hormone API sourcing with the required documentation, quality evidence, market, and supply route. Start with our US hormone API sourcing guide, then request an evidence package for your exact molecule and formulation program.